Hepatocyte Regeneration: The Molecular Biology of Liver Tissue Self-Repair Mechanisms

Overview

The mammalian liver occupies a unique physiological niche as the only visceral organ capable of full functional and structural restoration following significant tissue loss—a phenomenon termed compensatory hyperplasia. At the core of INNERSTANDIN’s investigation into hepatic resilience lies the hepatocyte, a highly specialised, quiescent cell that retains a potent, albeit tightly regulated, proliferative capacity. Unlike the regenerative processes observed in simpler vertebrates, human liver regeneration does not rely on a dedicated progenitor cell niche under standard conditions; rather, it involves the re-entry of mature, differentiated hepatocytes from the $G_0$ phase into the cell cycle. This orchestration is a multi-phasic molecular cascade, initiated by hemodynamic changes and a systemic surge in metabolic demand, requiring the precise integration of cytokine signalling, growth factor activation, and metabolic sensing.

The initiation, or 'priming' phase, is dictated by the immediate release of tumour necrosis factor-alpha (TNF-$\alpha$) and interleukin-6 (IL-6) from resident Kupffer cells. Research indexed in *The Lancet* and various PubMed-archived studies highlights that these cytokines are indispensable for transitioning hepatocytes into a state of replicative competence. Specifically, IL-6 binds to its cognate receptor, activating the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway. This molecular switch induces the expression of immediate-early genes, such as c-myc and c-fos, which sensitise the hepatocyte to subsequent mitogenic stimuli. Without this critical priming, the liver remains refractory to growth factors, leading to regenerative failure and subsequent hepatic encephalopathy or systemic organ collapse—a primary concern in clinical hepatology across the UK.

Following priming, the 'proliferation' phase is driven by potent mitogens, most notably Hepatocyte Growth Factor (HGF) and Epidermal Growth Factor (EGF). HGF, acting through the MET tyrosine kinase receptor, serves as the primary engine for DNA synthesis. The molecular complexity here is profound: the liver must balance massive cellular expansion with the preservation of vital metabolic functions, including bile acid synthesis and xenobiotic detoxification. At INNERSTANDIN, we recognise that this is not merely a cellular duplication event but a systemic recalibration. The Farnesoid X Receptor (FXR), a nuclear receptor central to bile metabolism, acts as a metabolic rheostat; rising levels of bile acids during tissue loss activate FXR, which in turn accelerates the regenerative cycle by modulating Cyclin D1 expression.

However, the "truth-exposing" reality of this biological marvel is its inherent risk. The termination phase, regulated by Transforming Growth Factor-beta (TGF-$\beta$) and activins, must precisely halt proliferation once the original liver-to-body-mass ratio is restored. Dysregulation at this juncture—often seen in chronic inflammatory states or alcohol-related liver disease prevalent in British clinical cohorts—leads to the pathological deposition of extracellular matrix. When the molecular brakes fail or the priming signals become chronic, the regenerative machinery is hijacked, transitioning from repair to fibrogenesis and, ultimately, hepatocellular carcinoma. Understanding these mechanisms is not merely academic; it is the frontier of regenerative medicine, providing the blueprint for bioengineered liver support systems and targeted pharmacological interventions to stimulate repair in failing organs.

The Biology — How It Works

The regenerative capacity of the human liver represents a pinnacle of biological engineering, a process technically classified as compensatory hyperplasia rather than true epimorphic regeneration. At the heart of INNERSTANDIN’s analysis of this phenomenon is the transition of hepatocytes from a state of mitotic quiescence (G0 phase) into a rigorous, programmed cell cycle (G1, S, G2, and M phases). This transition is orchestrated through a tripartite phase architecture: priming, progression, and termination, each governed by discrete molecular signals and systemic metabolic feedback.

The 'priming phase' is initiated by the rapid release of cytokines, primarily Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), largely secreted by Kupffer cells in response to tissue loss or toxic insult. These cytokines activate the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) and nuclear factor-kappa B (NF-κB) pathways. This molecular priming is essential because, under homeostatic conditions, mature hepatocytes are refractory to growth factors; these initial cytokine signals render them competent to respond to subsequent mitogenic stimuli.

Once primed, the 'progression phase' is dominated by potent primary mitogens, most notably Hepatocyte Growth Factor (HGF) and Epidermal Growth Factor (EGF). HGF, acting through its tyrosine kinase receptor, MET, triggers an intracellular signalling cascade involving the phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/ERK pathways. Peer-reviewed research, such as studies archived in PubMed and longitudinal analyses by the University of Edinburgh’s Centre for Regenerative Medicine, highlights that HGF levels in the blood rise up to twenty-fold within hours of hepatic resection. This influx drives the expression of Cyclin D1, the critical gatekeeper of the G1 to S phase transition, ensuring high-fidelity DNA replication across the parenchymal mass.

Simultaneously, the liver’s metabolic workload is redistributed amongst the remaining cells, a phenomenon INNERSTANDIN identifies as a crucial trigger for regeneration. Bile acid homeostasis plays a pivotal role here; the sudden increase in bile acid flux per hepatocyte activates the Farnesoid X Receptor (FXR). Research published in *The Lancet Gastroenterology & Hepatology* demonstrates that FXR activation induces the expression of Fibroblast Growth Factor 19 (FGF19 in humans, FGF15 in rodents), which synergises with HGF to accelerate the regenerative pace.

Finally, the 'termination phase' ensures the liver does not exceed its original mass, maintaining the 'hepatostat.' This is regulated by the Transforming Growth Factor-beta (TGF-β) superfamily and the Hippo signalling pathway. Specifically, the phosphorylation and subsequent cytoplasmic sequestration of the transcriptional co-activator YAP (Yes-associated protein) serve as a definitive molecular brake. Failure in these inhibitory circuits is a precursor to oncogenesis, underscoring why the precision of liver self-repair is a cornerstone of systemic survival in the UK’s clinical landscape. Through this rigorous molecular dialogue, the liver restores its functional architecture while preserving its critical metabolic and detoxification duties.

Mechanisms at the Cellular Level

The regenerative capacity of the liver is not merely a physiological curiosity but a masterclass in compensatory hyperplasia, orchestrated through a highly choreographed sequence of molecular signals that transition quiescent hepatocytes from the $G_0$ phase into an active cell cycle. Unlike the stem-cell-driven regeneration observed in the intestinal epithelium or haematopoietic system, the liver relies primarily on the proliferation of mature, differentiated cells to restore functional mass. This process is initiated by a "priming" phase, wherein the proinflammatory cytokines Tumour Necrosis Factor-alpha (TNF-$\alpha$) and Interleukin-6 (IL-6), predominantly secreted by resident Kupffer cells, activate the transcription factors NF-$\kappa$B and STAT3. This molecular switch is critical; it renders the hepatocyte responsive to subsequent mitogenic stimuli, effectively lowering the threshold for the transition into the $G_1$ phase.

Central to the proliferative drive is the Hepatocyte Growth Factor (HGF) and its cognate receptor, the Met tyrosine kinase. Evidence published in journals such as *The Lancet Gastroenterology & Hepatology* and *Nature Communications* underscores the potency of the HGF-Met axis, which, alongside Epidermal Growth Factor (EGF) and Transforming Growth Factor-alpha (TGF-$\alpha$), drives the expression of Cyclin D1. This advancement through the restriction point is the point of no return for cellular division. At INNERSTANDIN, we recognise that this is not an isolated cellular event but a systemic response. The British liver research community, notably at the University of Edinburgh’s Centre for Regenerative Medicine, has highlighted the role of the Extracellular Matrix (ECM) in this phase. The rapid degradation of the ECM by matrix metalloproteinases (MMPs) releases sequestered growth factors, simultaneously altering the mechanical tension of the liver scaffold, which provides a physical cue for proliferative expansion.

The metabolic context of regeneration is equally paramount. The liver must maintain its critical functions—specifically bile acid metabolism and glucose homeostasis—while the cellular machinery is diverted toward replication. The Farnesoid X Receptor (FXR), a nuclear receptor sensitive to bile acid concentrations, acts as a metabolic rheostat. Research indexed in PubMed demonstrates that FXR activation is indispensable for timely regeneration; it coordinates the expansion of the bile acid pool with the growth of the liver tissue, preventing cholestatic injury during the regenerative window. Furthermore, the Wnt/$\beta$-catenin signalling pathway, integrated with the Hippo-YAP circuit, ensures that the liver does not exceed its original anatomical volume. The YAP (Yes-associated protein) acts as a sensor of organ size, translocating to the nucleus to drive pro-growth genes until the precise "hepatostat" set-point is reached.

The termination phase is as critical as the initiation. To prevent runaway hyperplasia and potential oncogenesis, the liver employs Transforming Growth Factor-beta (TGF-$\beta$) and activins as potent antimitogens. These proteins halt the cell cycle and initiate the restoration of the mature epithelial-mesenchymal architecture. Failure in these feedback loops is a hallmark of chronic liver disease and cirrhosis, where the regenerative drive becomes maladaptive. Understanding these cellular mechanisms at the high-density molecular level provided by INNERSTANDIN reveals the liver's self-repair as a sophisticated, redundant, and highly regulated biological programme that ensures systemic survival against toxicological and physical insult.

Environmental Threats and Biological Disruptors

The regenerative capacity of the human liver is a marvel of evolutionary engineering, yet this compensatory hyperplasia is increasingly besieged by a cocktail of anthropogenic disruptors that subvert the molecular machinery of repair. While the liver is physiologically designed to neutralise xenobiotics, the sheer volume and persistence of modern environmental pollutants have begun to outpace the kinetic limits of hepatocyte proliferation. At the heart of this disruption is the corruption of the nuclear receptor signalling pathways—specifically the Constitutive Androstane Receptor (CAR) and the Pregnane X Receptor (PXR). These sensors, evolved to detect and metabolise natural toxins, are now chronically ligated by Persistent Organic Pollutants (POPs) and Endocrine Disrupting Chemicals (EDCs). This chronic activation leads to a state of "metabolic exhaustion," where the hepatocyte’s energy budget is diverted from DNA synthesis and mitotic progression towards the perpetual expression of Phase I and II detoxification enzymes, effectively stalling the regenerative cell cycle in the G1 phase.

Within the UK landscape, the prevalence of perfluoroalkyl substances (PFAS)—frequently identified in water catchment areas—poses a profound threat to hepatic integrity. Research published in *The Lancet Planetary Health* underscores how these "forever chemicals" interfere with the Hepatocyte Growth Factor (HGF)/c-Met signalling axis. PFAS molecules exhibit a high affinity for peroxisome proliferator-activated receptor alpha (PPARα), but rather than triggering controlled lipid metabolism, they induce a dysregulated, pro-inflammatory state that inhibits the nuclear translocation of β-catenin. Without the robust activation of the Wnt/β-catenin pathway, the liver cannot orchestrate the precise wave of hepatocyte division required to replace damaged parenchyma, leading instead to the deposition of fibrotic extracellular matrix—a hallmark of failed regeneration.

Furthermore, the bioaccumulation of microplastics and nanoplastics, now routinely detected in the human portal vein, introduces a mechanical and immunological barrier to self-repair. These particles trigger chronic activation of Kupffer cells, the liver’s resident macrophages. At INNERSTANDIN, we recognise that while acute Kupffer cell activation is essential for the "priming" phase of regeneration via the release of Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), chronic exposure results in a desensitisation of the gp130 receptor. This desensitisation renders hepatocytes deaf to the very signals that should initiate the transition from G0 to G1.

The synergistic impact of alcohol-derived acetaldehyde further complicates this landscape. Acetaldehyde creates DNA-protein crosslinks that are particularly lethal to regenerating cells. In the context of the UK’s heavy burden of Alcohol-related Liver Disease (ArLD), the molecular failure lies in the exhaustion of the Fanconi Anaemia (FA) repair pathway. When environmental xenobiotics and ethanol metabolites converge, they saturate the cell's ability to resolve interstrand crosslinks during S-phase. The result is a catastrophic failure of the regenerative niche, where the liver’s innate biological intelligence is silenced by an environment it was never evolved to withstand. This is not merely a failure of a single organ, but a systemic breakdown of the liver’s role as the sentinel of human homeostasis.

The Cascade: From Exposure to Disease

The transition from homeostatic quiescence to pathological deterioration is not a linear decline but a complex, multi-stage molecular cascade where the liver’s regenerative machinery becomes its own antagonist. In the UK, the escalating burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and alcohol-related liver disease (ARLD) provides a sobering backdrop for this transition. At the heart of INNERSTANDIN’s investigation into this cascade is the disruption of the compensatory hyperplasia mechanism. Normally, hepatocytes exist in a state of G0 quiescence; however, upon exposure to acute or chronic insults—be it ethanol-derived acetaldehyde or lipotoxicity—they are 'primed' to re-enter the cell cycle. This priming phase is orchestrated by a cytokine-mediated influx, primarily Tumour Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6) secreted by resident Kupffer cells. These signals activate the NF-κB and STAT3 pathways, transitioning the hepatocyte into the G1 phase.

As the cascade progresses, the failure of the regenerative response is often dictated by the persistence of the noxious stimulus. In chronic scenarios, the high-fidelity replication of parenchymal tissue is superseded by the activation of Hepatic Stellate Cells (HSCs). Research published in *The Lancet Gastroenterology & Hepatology* highlights that when the regenerative capacity of hepatocytes is overwhelmed or inhibited by oxidative stress, the liver shifts its strategy from cellular replacement to structural scarring. The molecular switch here is the upregulation of Transforming Growth Factor-beta (TGF-β), which serves as a potent inhibitor of hepatocyte proliferation while simultaneously driving the transdifferentiation of HSCs into myofibroblasts. This produces an aberrant accumulation of Type I and III collagen within the Space of Disse, culminating in the "capillarisation" of the sinusoids. This structural alteration severely impairs the bi-directional exchange of nutrients and metabolites, directly impacting bile acid homeostasis.

Furthermore, the cascade involves a profound dysregulation of the Farnesoid X Receptor (FXR) and the G protein-coupled bile acid receptor (TGR5). In a healthy regenerative state, bile acids act as signalling molecules to accelerate liver repair; however, in the diseased cascade, the accumulation of hydrophobic bile acids induces hepatocyte apoptosis and triggers the "ductular reaction"—an expansion of biliary epithelial cells that signifies a desperate, albeit often dysfunctional, attempt at tissue repair. This biliary stasis further exacerbates systemic inflammation. Evidence from PubMed-indexed longitudinal studies suggests that in the UK clinical context, the "point of no return" in this cascade is reached when the regenerative nodules, characteristic of cirrhosis, fail to maintain vascular integration. At this stage, the molecular focus shifts from proliferation to oncogenic transformation, as the chronic proliferative pressure and DNA damage from reactive oxygen species (ROS) create a microenvironment ripe for hepatocellular carcinoma (HCC). INNERSTANDIN posits that the molecular biology of this cascade is not merely a sequence of damage, but a systematic failure of the liver’s epigenetic and transcriptional regulatory networks to balance repair with architectural integrity.

What the Mainstream Narrative Omits

The mainstream discourse surrounding hepatic resilience often reduces hepatocyte regeneration to a simplistic model of compensatory hyperplasia following acute insult. However, this pedestrian view omits the sophisticated spatiotemporal regulation and metabolic cost of "regenerative exhaustion" that characterizes modern chronic pathology. At INNERSTANDIN, our synthesis of recent proteomic and transcriptomic data reveals that the liver does not merely "regrow"; it undergoes a complex epigenetic recalibration that is frequently compromised by the UK’s prevailing metabolic landscape.

Primary among the omissions is the critical role of metabolic zoning. Conventional narratives treat the liver as a homogeneous mass, yet regenerative capacity is strictly dictated by the Wnt/β-catenin signalling gradient. Research indexed in *PubMed* highlights that perivenous hepatocytes, which operate under lower oxygen tension, possess a distinct molecular signature compared to periportal cells. When this architectural hierarchy is disrupted by chronic inflammation or steatosis—prevalent in the UK due to the high consumption of ultra-processed carbohydrates—the "zonal" instructions for repair are corrupted. This results in "frustrated regeneration," where the liver attempts to replace mass but fails to restore the intricate micro-circulatory flow necessary for detoxification.

Furthermore, the mainstream narrative largely ignores the "ductular reaction" and the activation of Hepatic Progenitor Cells (HPCs). In states of chronic injury where mature hepatocytes reach replicative senescence—often evidenced by telomere shortening—the liver recruits these facultative stem cells. However, if the extracellular matrix (ECM) is excessively stiffened by fibrosis, these progenitor cells are misdirected toward a myofibroblastic fate rather than becoming functional hepatocytes. This molecular "bait-and-switch" is a precursor to hepatocellular carcinoma, yet it remains under-discussed in clinical primary care.

Equally overlooked is the gut-liver axis’s role in signalling repair. Evidence in *The Lancet* suggests that bile acids, specifically through the Farnesoid X Receptor (FXR) and TGR5 pathways, act as potent mitogens. In the British population, widespread dysbiosis and gallbladder dysfunction impair this signalling. Without the correct biliary-to-portal feedback, the liver lacks the "stop" and "start" signals required for precise volumetric control. At INNERSTANDIN, we posit that the failure to address these molecular nuances—the transition from quiescence to the G1 phase of the cell cycle—is why "liver health" supplements and generic advice fail. We must move beyond the myth of the "invincible liver" and acknowledge that without specific micronutrient co-factors and a pristine signalling environment, the liver's regenerative potential is a finite resource that can, and does, expire.

The UK Context

In the United Kingdom, the epidemiological landscape of hepatobiliary pathology presents a critical challenge to the innate regenerative capacity of the liver. Data from the Lancet Commission on Liver Disease underscore a staggering 400% increase in liver-related mortality since 1970, a phenomenon that directly intersects with the molecular exhaustion of hepatocyte proliferation. INNERSTANDIN identifies that the regenerative niche within the British population is increasingly compromised by systemic metabolic dysfunction, shifting the liver's state from homeostatic repair to pathological scarring.

At the molecular level, the transition of hepatocytes from the quiescent G0 phase into the cell cycle is governed by a precise 'priming' sequence. In the UK context, where Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) affects approximately one-third of the population, this priming mechanism—typically mediated by Interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) from Kupffer cells—is often chronically dysregulated. Research from the University of Edinburgh’s Centre for Regenerative Medicine suggests that chronic low-grade inflammation leads to a state of 'replicative senescence' in the hepatic progenitor cell (HPC) compartment. This is not merely a loss of function but a systemic failure of the Hippo signalling pathway and the Yap/Taz transcriptional co-activators, which are essential for determining organ size and orchestrating tissue repair.

Furthermore, the UK’s high prevalence of Alcohol-related Liver Disease (ARLD) introduces acute oxidative stress that disrupts the HGF (Hepatocyte Growth Factor) and c-Met receptor axis. The aberrant deposition of type I collagen within the Space of Disse, a hallmark of the fibrotic progression seen in NHS clinical audits, physically and chemically inhibits the mitogenic signals required for hepatocyte cytokinesis. INNERSTANDIN posits that the saturation of bile acid pools—specifically the dysregulation of the Farnesoid X Receptor (FXR) and the TGR5 signalling cascade—further suppresses the regenerative potential by blunting the proliferative response to liver injury. This molecular inertia, driven by contemporary British dietary patterns and toxicological exposures, effectively 'locks' the liver in a pro-fibrotic rather than a pro-regenerative state. Evidence published in PubMed confirms that without the restoration of these molecular triggers, the liver’s storied capacity for self-repair remains an untapped biological potential, stifled by the systemic pressures of the 21st-century British environment.

Protective Measures and Recovery Protocols

To facilitate robust hepatocyte proliferation and ensure the fidelity of genomic replication during the compensatory hyperplasia that characterises liver regeneration, the biochemical environment must be meticulously calibrated. At the forefront of protective protocols is the augmentation of the intracellular thiol pool, specifically via the administration of N-acetylcysteine (NAC). While clinically utilised in the UK within the paracetamol overdose protocol (the "Toxbase" standard), its molecular utility extends to all forms of acute hepatic insult. NAC serves as a precursor to glutathione (GSH), providing the rate-limiting substrate, cysteine, for glutamate-cysteine ligase. Restoring GSH levels is not merely an antioxidant measure; it is a fundamental requirement for the $S$-phase of the cell cycle, as hepatocyte DNA synthesis is exquisitely sensitive to the redox state. Research indexed in *The Lancet Gastroenterology & Hepatology* underscores that maintaining mitochondrial redox homeostasis prevents the transition of the mitochondrial permeability transition pore (mPTP), thereby averting cytochrome c release and subsequent apoptotic cascades that would otherwise abort the regenerative programme.

Furthermore, true INNERSTANDIN of liver recovery necessitates a focus on the bile acid-activated farnesoid X receptor (FXR). The gut-liver axis acts as a critical rheostat for regeneration; as hepatocytes are lost, the bile acid pool increases relative to the remaining functional tissue. Activation of FXR by primary bile acids, such as chenodeoxycholic acid, triggers the expression of fibroblast growth factor 19 (FGF19 in humans; FGF15 in murine models), which circulates back to the liver to repress bile acid synthesis while simultaneously stimulating the expression of Foxm1b. This transcription factor is a non-negotiable requirement for the transition from $G_{1}$ to $S$ phase and $G_{2}$ to $M$ phase. Consequently, pharmacological or nutritional strategies that support FXR signalling—and by extension, the enterohepatic circulation—are pivotal in synchronising the timing of hepatocyte entry into the cell cycle.

Equally vital is the maintenance of autophagic flux. Autophagy serves as a quality-control mechanism, degrading damaged organelles and protein aggregates that accumulate during metabolic stress. In the context of regeneration, mitophagy—the selective autophagy of mitochondria—is essential to remove dysfunctional mitochondria that generate excessive reactive oxygen species (ROS), which can lead to telomere attrition and replicative senescence. Experimental data from PubMed-indexed studies suggest that caloric restriction or the use of mimetic compounds like spermidine can enhance this autophagic clearance, thereby ensuring that the newly formed daughter cells possess a high-fidelity metabolic apparatus.

Finally, the chronobiological aspect of hepatic repair cannot be overlooked. The liver is a highly rhythmic organ, with nearly 40% of its transcriptome under the control of the BMAL1/CLOCK heterodimer. Recovery protocols must respect the hepatic circadian rhythm, as the expression of Wee1 (a key inhibitor of the Cdc2/Cyclin B complex) is rhythmically regulated. Disrupting this cycle—common in shift workers or through nocturnal feeding—desynchronises the cell cycle, leading to genomic instability and a significantly protracted recovery period. True regenerative success, therefore, relies on a systems-biology approach that integrates redox restoration, nuclear receptor signalling, and the preservation of cellular rhythms.

Summary: Key Takeaways

The biological capacity for hepatocyte regeneration represents a pinnacle of mammalian evolutionary resilience, shifting the paradigm from simple tissue repair to a sophisticated orchestration of compensatory hyperplasia. At the core of this INNERSTANDIN exploration is the fundamental truth that mature, quiescent hepatocytes (G0 phase) possess an unparalleled latent proliferative potential, re-entering the cell cycle (G1 phase) through a highly coordinated cytokine-growth factor cascade. Evidence documented across PubMed and high-impact journals like *The Lancet* underscores the critical roles of the IL-6/STAT3 and TNF-α signalling pathways in priming the liver for mitotic expansion. This is followed by a definitive proliferative phase driven by Hepatocyte Growth Factor (HGF) and Epidermal Growth Factor (EGF), acting via the c-Met and EGFR receptors respectively.

Crucially, this regenerative programme is inextricably linked to bile metabolism; farnesoid X receptor (FXR) activation by primary bile acids serves as a metabolic sensor that synchronises hepatocyte proliferation with functional demand, preventing cholestatic injury during the expansion phase. UK-led research, particularly from institutions like the University of Edinburgh’s Centre for Regenerative Medicine, highlights that failures in these molecular checkpoints often lead to fibrotic progression or hepatocarcinogenesis. Ultimately, the systemic impact of this repair mechanism ensures the maintenance of critical metabolic homeostasis—ranging from xenobiotic detoxification to glucose regulation—affirming the liver's role as a self-correcting bio-engine. The molecular integrity of these regenerative pathways is the true determinant of hepatic longevity and systemic vitality within the human organism.